Overview

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge

Phase:

Phase 3

Details

Lead Sponsor:

Thomas L. Ortel
Thomas Ortel, M.D., Ph.D.

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Apixaban